STERIS plc $STE Shares Sold by Mackenzie Financial Corp

Mackenzie Financial Corp reduced its stake in STERIS plc by 36.4% in Q2, now holding 11,804 shares worth $2.84 million. Other institutional investors like Orbis Allan Gray Ltd and Norges Bank have acquired significant stakes. Insider sales include VP Renato Tamaro selling 5,036 shares. STERIS reported Q2 earnings of $2.47 per share, beating estimates, with revenue of $1.46 billion. The company declared a quarterly dividend of $0.63 per share. Analysts have given positive ratings, with Morgan Stanley raising the price target to $295.

Mackenzie Financial Corp lowered its stake in shares of STERIS plc (NYSE:STE - Free Report) by 36.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 11,804 shares of the medical equipment provider's stock after selling 6,748 shares during the quarter. Mackenzie Financial Corp's holdings in STERIS were worth $2,836,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Orbis Allan Gray Ltd purchased a new position in shares of STERIS in the 1st quarter valued at approximately $349,950,000. Norges Bank acquired a new stake in shares of STERIS during the second quarter worth $289,132,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in STERIS by 55.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,520,479 shares of the medical equipment provider's stock valued at $344,617,000 after buying an additional 540,999 shares during the last quarter. Nuveen LLC acquired a new position in STERIS in the 1st quarter valued at $65,435,000. Finally, Vanguard Group Inc. raised its position in STERIS by 1.7% during the 2nd quarter. Vanguard Group Inc. now owns 12,163,128 shares of the medical equipment provider's stock worth $2,921,827,000 after buying an additional 205,276 shares during the last quarter. 94.69% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at STERIS

In other STERIS news, VP Renato Tamaro sold 5,036 shares of STERIS stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $257.55, for a total transaction of $1,297,021.80. Following the completion of the transaction, the vice president owned 5,695 shares in the company, valued at approximately $1,466,747.25. The trade was a 46.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Julia Madsen sold 5,008 shares of the company's stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $262.00, for a total transaction of $1,312,096.00. Following the completion of the sale, the vice president directly owned 10,710 shares in the company, valued at $2,806,020. This trade represents a 31.86% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 25,203 shares of company stock valued at $6,624,667 over the last 90 days. 1.07% of the stock is currently owned by corporate insiders.

STERIS Stock Up 0.6%

STE stock opened at $260.93 on Friday. STERIS plc has a 52 week low of $200.98 and a 52 week high of $268.60. The company has a current ratio of 2.37, a quick ratio of 1.63 and a debt-to-equity ratio of 0.27. The company has a market cap of $25.61 billion, a P/E ratio of 37.49 and a beta of 1.01. The company's 50-day moving average price is $249.71 and its 200 day moving average price is $243.39.

STERIS (NYSE:STE - Get Free Report) last announced its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 EPS for the quarter, topping the consensus estimate of $2.38 by $0.09. The business had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. STERIS had a return on equity of 14.43% and a net margin of 12.07%.During the same quarter in the previous year, the company earned $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. On average, research analysts expect that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 18th. Stockholders of record on Tuesday, November 18th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, November 18th. STERIS's payout ratio is 36.21%.

Analyst Ratings Changes

Several analysts have recently weighed in on STE shares. Weiss Ratings reaffirmed a "buy (b)" rating on shares of STERIS in a report on Tuesday, October 14th. Morgan Stanley raised their price objective on shares of STERIS from $276.00 to $295.00 and gave the company an "overweight" rating in a research report on Friday, August 8th. Finally, Wall Street Zen upgraded STERIS from a "buy" rating to a "strong-buy" rating in a research report on Sunday, September 14th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $273.50.

Read Our Latest Stock Report on STERIS

About STERIS

(Free Report)

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

Should You Invest $1,000 in STERIS Right Now?

Before you consider STERIS, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.

While STERIS currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here